Is Zegalogue Approved for Babies?
Zegalogue (dasiglucagon) is FDA-approved for treating severe hypoglycemia in adults and children aged 6 years and older who weigh at least 16 kg (about 35 lbs). It is not approved for infants or babies under 6 years old, or those weighing less than 16 kg.[1]
What About Use in Infants Under 6 Years?
No pediatric approval exists for babies or very young children. Clinical trials supporting approval focused on patients 6 years and older, with safety and efficacy data limited to that group. The 16 kg weight minimum aligns with autoinjector design for reliable dosing.[1][2]
Why the Age and Weight Restrictions?
Zegalogue's approval stems from two trials in patients aged 6+ years, showing it raises blood glucose faster than placebo or glucagon within 30 minutes. No trials tested it in infants, where smaller body size, immature metabolism, and different hypoglycemia causes (like inborn errors) raise safety concerns. Off-label use in neonates or infants lacks supporting data and isn't recommended.[2][3]
Alternatives for Babies with Hypoglycemia?
For infants, standard treatment is intravenous glucose (e.g., D10W solution) or glucagon via IV/IM if access is delayed. Glucagon kits like Glucagon Emergency Kit are approved down to neonates but require reconstitution, unlike Zegalogue's ready-to-use pen. Mini-doses (0.02-0.03 mg/kg) are sometimes used off-label in pediatrics.[3][4]
Risks of Using Zegalogue in Babies?
Potential issues include overdose from fixed 0.6 mg dose (too high for tiny patients), injection site reactions, nausea/vomiting, and unknown long-term effects in neonates. The FDA label warns against use below 16 kg due to insufficient data.[1]
[1]: FDA Label for Zegalogue
[2]: Zegalogue Prescribing Information
[3]: American Diabetes Association Standards of Care in Diabetes—2023
[4]: Glucagon Use in Pediatric Hypoglycemia - Pediatric Endocrine Society